XLV - Health Care Select Sector SPDR ETF

NYSEArca - Nasdaq Real Time Price. Currency in USD
92.23
+1.79 (+1.98%)
As of 11:21AM EDT. Market open.
Stock chart is not supported by your current browser
Previous close90.44
Open91.14
Bid0.00 x 2200
Ask0.00 x 1000
Day's range91.14 - 92.28
52-week range78.74 - 96.06
Volume5,112,381
Avg. volume7,641,596
Net assets19.61B
NAV95.11
PE ratio (TTM)N/A
Yield1.38%
YTD return16.36%
Beta (3Y Monthly)0.93
Expense ratio (net)0.14%
Inception date1998-12-16
Trade prices are not sourced from all markets
  • How Is Medtronic Positioned in October?
    Market Realistyesterday

    How Is Medtronic Positioned in October?

    In the first quarter of fiscal 2019, Medtronic generated net revenues of $7.4 billion, a ~0.1% year-over-year (or YoY) decline. Wall Street analysts estimate that Medtronic will generate revenues of $7.3 billion in the second quarter of fiscal 2019.

  • ABT Stock Fell ~3.3% on October 10 despite Analyst Upgrade
    Market Realist5 days ago

    ABT Stock Fell ~3.3% on October 10 despite Analyst Upgrade

    On October 10, Abbott Laboratories (ABT) ended the trading day at $68.92, down ~3.3% from the previous day’s close. On the day, Morgan Stanley raised its target price on ABT stock from $70 to $80. However, the stock price dropped as the broader market sell-off pulled down ABT stock prices along with a large number of other healthcare stocks. The SPDR S&P 500 ETF (SPY) was down ~3.2% on October 10.

  • Healthcare Stocks in the Red amid Broader Market Sell-Off
    Market Realist5 days ago

    Healthcare Stocks in the Red amid Broader Market Sell-Off

    Yesterday, most healthcare stocks were trading below their previous day’s closing price. Biotech players seem to have been hit the worst. However, all other sectors including pharmaceuticals, medical devices, and hospitals saw significant weakness. Johnson & Johnson (JNJ), Boston Scientific (BSX), Pfizer (PFE), Merck (MRK), and Bristol-Myers Squibb fell 1.1%, 2.1%, 2.6%, and 3.9%, respectively, yesterday. Major biotechnology players Gilead Sciences (GILD), Amgen (AMGN), Biogen (BIIB), and Novo Nordisk (NVO) fell 2.30%, 2.33%, 2.04%, and 1.81%, respectively.

  • Celgene: Analysts’ Views before Its Third-Quarter Earnings
    Market Realist6 days ago

    Celgene: Analysts’ Views before Its Third-Quarter Earnings

    Wall Street analysts expect Celgene to report a net income and EPS of $1.2 billion and $1.71, respectively, in the third quarter.

  • Allergan’s Neurology Portfolio, Stock Performance, and Ratings
    Market Realist7 days ago

    Allergan’s Neurology Portfolio, Stock Performance, and Ratings

    On October 3, Allergan’s (AGN) stock price closed at $193.46, which is ~11.0% below its 52-week high of $215.10 on October 3, 2017. Allergan’s stock price grew from $164.05 at the open of the market on January 2 to $193.46 on October 3, which reflects ~18.0% YTD (year-to-date) growth. On March 5, Merck hit its 52-week low of $142.81.

  • US Unemployment at 49-Year Low: How Did the Markets React?
    Market Realist11 days ago

    US Unemployment at 49-Year Low: How Did the Markets React?

    The US jobs report for September was released on October 5. While the jobs report was mixed, there were enough signs that the labor market was tightening, which would eventually lead to wage growth gains.

  • UnitedHealth Group Stock Hit 52-Week High on October 3
    Market Realist12 days ago

    UnitedHealth Group Stock Hit 52-Week High on October 3

    UNH Stock Hits 52-Week High: Can It Sustain the Momentum?UnitedHealth Group’s recent trading activity

  • Top Performing ETFs of the Third Quarter
    Zacks12 days ago

    Top Performing ETFs of the Third Quarter

    Healthcare emerged as the new leader in Q3. Here is what investors need to know about best performing sectors and ETFs.

  • Job Growth in September Could Surprise to the Upside
    Market Realist12 days ago

    Job Growth in September Could Surprise to the Upside

    Economists expect the US economy to add 180,000 jobs in September—below the 201,000 job additions reported in August and the average monthly gain of 196,000 over the previous 12 months. Economists’ estimate for job additions could have an upside, according to data from ADP and Moody’s Analytics. Based on the data released on October 3, private companies added 230,000 more jobs in September—much higher than the expectations of 184,000 jobs. The job additions were the highest level since 241,000 job additions in February.

  • Mylan Stock Declined ~12% Year-to-Date: Could It Recover Soon?
    Market Realist15 days ago

    Mylan Stock Declined ~12% Year-to-Date: Could It Recover Soon?

    The closing price for Mylan (MYL) stock on September 25 was $23.27, and its market capitalization stood at $19.4 billion. The stock registered its 52-week high of $47.82 on January 23 and its 52-week low of $30.73 on September 28. Currently, Mylan stock is trading above its 50-day moving average of $23.18 as well as its 200-day moving average of $21.39.

  • EW Stock Returned More than the S&P 500’s Gain in 2018
    Market Realist15 days ago

    EW Stock Returned More than the S&P 500’s Gain in 2018

    As of September 28, Edwards Lifesciences (EW) has registered a rise of ~52.5% YTD (year-to-date). In the same period, the S&P 500 has risen ~9.2%.

  • ALGN Stock Surpasses the S&P 500 Index’s Year-to-Date Gain
    Market Realist15 days ago

    ALGN Stock Surpasses the S&P 500 Index’s Year-to-Date Gain

    ALGN Stock Surpasses the S&P 500 Index’s Year-to-Date GainAlign Technology surpassed the S&P 500 Index’s gains

  • Health care is having its best quarter in five years, and one winner is set to keep surging
    CNBC18 days ago

    Health care is having its best quarter in five years, and one winner is set to keep surging

    The S&P 500 health-care sector has been on a tear in recent months, on track for its best quarter in five years and surging to an all-time high on Friday. Names such as Eli Lilly, Biogen and Pfizer are among the biggest winners in the last three months, with double-digit gains. According to one chart-minded analyst, Biogen is one name in the space set to continue rallying.

  • EW Traded at Its 52-Week High on September 28
    Market Realist18 days ago

    EW Traded at Its 52-Week High on September 28

    On September 27, Edwards Lifesciences (EW) ended trading at a closing price of $172.16. The stock traded at its record high of $172.54 on September 27. The stock continued its bull run after it increased ~7.7% on September 25. A Wells Fargo analyst suggested Edwards Lifesciences or Boston Scientific as the potential acquisitions for Johnson & Johnson (JNJ). The company registered strong second-quarter results on July 26. However, the stock registered a fall of ~5.8% in the after-hours trading. Since then, Edwards Lifesciences stock has risen ~22%. ...

  • Investor's Business Daily19 days ago

    Techs Lift Stock Market, But This Other Sector Stands Out

    The technology sector climbed Thursday, helping the Nasdaq composite lead. But the health care sector was even stronger.

  • UnitedHealth Stock Hit 52-Week High in September: What’s Next?
    Market Realist21 days ago

    UnitedHealth Stock Hit 52-Week High in September: What’s Next?

    On September 24, UnitedHealth Group (UNH) ended the trading day at $267.36. The stock was marginally up ~0.26% from its previous day’s closing price. It hit its 52-week high of $271.16 on September 7. UNH stock was trading at its 52-week low of $186 on October 13, 2017.

  • Why JNJ Stock Rose ~2.4% Last Week
    Market Realist22 days ago

    Why JNJ Stock Rose ~2.4% Last Week

    On September 21, Johnson & Johnson (JNJ) stock closed at $142.88, ~0.63% higher than the previous day’s closing price of $141.98. JNJ stock returned ~2.4% last week and is currently trading above its 50-day and 200-day moving averages of $135.35 and $128.52, respectively.

  • Why Merck Stock Has Risen 28.2% Year-to-Date
    Market Realist25 days ago

    Why Merck Stock Has Risen 28.2% Year-to-Date

    Merck (MRK) stock has risen from $54.93 on January 2 to $70.42 on September 18—a 28.2% increase year-to-date. The performance of Merck stock has been closely related to the sales, clinical trial outcomes, and regulatory decisions for the company’s leading immuno-oncology drug, Keytruda. Approved in 13 indications and eight tumor types, Keytruda reported sales of $1.7 billion in the second quarter.

  • Alphabet, Facebook and Netflix are about to destroy the stock market's biggest dividend trade
    CNBC25 days ago

    Alphabet, Facebook and Netflix are about to destroy the stock market's biggest dividend trade

    The S&P 500 has a big problem: too much return from a handful of technology stocks. It has a plan to fix that, and it goes into effect next Monday morning, when major tech stocks, including Facebook, Alphabet and Netflix, are on the move into new S&P sectors, with big implications for investors.

  • ABT Returns Almost Double the S&P 500’s Year-to-Date Gain
    Market Realist26 days ago

    ABT Returns Almost Double the S&P 500’s Year-to-Date Gain

    As of September 19, Abbott Laboratories (ABT) has registered a rise of ~17% YTD (year-to-date). In the same period, the S&P 500 has risen ~8%. Abbott Laboratories has clearly surpassed the market’s returns so far in 2018.

  • Why Is BSX Stock Trading at Its 14-Year High Today?
    Market Realistlast month

    Why Is BSX Stock Trading at Its 14-Year High Today?

    Currently, BSX stock is trading near its all-time high. Boston Scientific (BSX) stock has been on a bullish trend over the last year, driven by strong fundamentals, a robust acquisition strategy, and a diverse product pipeline. Why did BSX stock jump today?

  • JNJ Stock Up 7% in the Past Month: What Drove the Bulls?
    Market Realistlast month

    JNJ Stock Up 7% in the Past Month: What Drove the Bulls?

    On September 12, Johnson & Johnson (JNJ) stock closed at $139.36. That was a 0.61% rise from the previous day’s closing price of $138.51. Currently, JNJ stock is trading above its 50-day moving average of $133.29 and below its 200-day moving average of $127.99.

  • Eli Lilly Initiates New Trial for Taltz in Plaque Psoriasis
    Market Realistlast month

    Eli Lilly Initiates New Trial for Taltz in Plaque Psoriasis

    Eli Lilly (LLY) announced in a press release on September 10 that the company has initiated the IXORA-R head-to-head (or H2H) study evaluating the superiority of drugs Taltz (ixekizumab) and Tremfya (guselkumab) in patients with moderate-to-severe plaque psoriasis. The below chart shows key highlights for the IXORA-R H2H trial.

  • CNBClast month

    A market bull gives 3 winning stock picks through next year

    B. Riley FBR's Art Hogan says he's "afraid of anything that looks like a bond."

  • UnitedHealth Group Stock at 52-Week High, Up 22% Year-to-Date
    Market Realistlast month

    UnitedHealth Group Stock at 52-Week High, Up 22% Year-to-Date

    On September 5, UnitedHealth Group (UNH) ended the trading day at $267.64. The stock was marginally down from its previous day’s closing price. However, the stock registered its 52-week high of $270.17 last week on August 30. It was trading at its 52-week low of $186 on October 13, 2017.